Gene Therapy Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

The gene therapy market was valued at USD 9.59 Billion in 2025. It is poised to grow at a CAGR of 22.80% during the forecast period of 2026-2035, and reach USD 74.78 Billion by 2035. The rising prevalence of genetic disorders and increasing investment in advanced medical research are key drivers of the market.

Key Market Trends and Insights

• By indication, oncological disorders accounted for over 44% of the market in the historical period.
• By vector type, viral vectors held more than 74% of the market share in the historical period.
• By geography, North America captured approximately 41% of the market in the historical period.

Market Size and Forecast

• Market Size (2025): USD 9.59 Billion
• Projected Market Size (2035): USD 74.78 Billion
• CAGR (2026-2035): 22.80%

Gene Therapy Market Overview

The market is rapidly expanding, driven by advancements in genetic engineering, viral and non-viral vector technologies, and the increasing prevalence of rare and inherited diseases. Rising regulatory approvals, growing R&D investments, and improved clinical trial success rates are accelerating adoption. Innovative treatments targeting oncology, genetic disorders, and rare diseases are shaping the market, supporting long-term growth globally. The market reached a value of approximately USD 9.59 Billion in 2025.

Gene Therapy Market Growth Drivers

Regulatory Support Driving Rare Disease Treatment Market Expansion

Rising demand for innovative treatments and strong regulatory backing are fueling gene therapy adoption. For instance, in April 2026, the FDA accepted Ultragenyx’s resubmitted Biologics License Application for UX111 targeting Sanfilippo syndrome Type A, a rare disorder. This milestone underscores ongoing progress in rare disease gene therapy, encouraging investment, accelerating clinical development, and supporting market growth globally.

Gene Therapy Market Trends

Key trends shaping the market include rising rare disease focus, regulatory support, advanced therapies, and gene editing innovations.

Breakthrough Designations Enhancing Market Development

Growing focus on advanced therapies and increasing R&D investments drive market evolution. For instance, in March 2026, MeiraGTx’s AAV2‑hAQP1 gene therapy for radiation-induced xerostomia received FDA Breakthrough Therapy Designation. This regulatory recognition of gene augmentation solutions boosts innovation, validates clinical potential, and strengthens long-term development opportunities across the market.

Gene Therapy Market Segmentation

Market Breakup by Indication

• Neurological Disorder
• Oncological Disorders
• Rare Diseases
• Eye Disorders
• Others

Market Breakup by Vector

• Non-Viral Vector
• Oligonucleotides
• Others
• Viral Vector
• Retroviral Vectors
• Adeno-associated Viral Vectors
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Gene Therapy Market Share

Viral Vectors Expected to Dominate the Market Segment by Vector Type

By vector type, viral vectors dominated the segment in the historical period, accounting for over 74% of the total market share. The preference for viral vectors is driven by their high efficiency in gene transfer, established clinical success, and versatility across multiple indications. This dominance highlights the ongoing reliance on proven delivery systems to accelerate gene therapy development globally.

Gene Therapy Market Analysis by Region

North America captured approximately 41% of the market during the historical period. Strong regulatory support, high R&D investment, and early adoption of advanced treatments, including rare disease gene therapy, are key drivers. The region continues to lead in clinical trials, commercialization, and technology development, reinforcing its position in the global market.

Leading Players in the Gene Therapy Market

The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Novartis AG

Novartis AG, headquartered in Basel, Switzerland, and founded in 1996, is a global biopharmaceutical leader with extensive gene therapy portfolios, including onasemnogene abeparvovec and Itvisma for spinal muscular atrophy. The company focuses on rare diseases, oncology, and neurologic conditions, leveraging advanced vector and delivery platforms. A recent gene correction milestone is FDA approval of Itvisma for broader spinal muscular atrophy (SMA) patients.

Amgen Inc.

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a biotechnology firm focused on innovative therapies for oncology, cardiovascular, and rare diseases. While primarily known for biologics and antibody therapies, Amgen’s pipeline includes cutting edge genetic approaches and collaborations to expand its therapeutic reach through in vivo vs ex vivo strategies, along with external innovation partnerships like AAVantgarde and Dark Blue Therapeutics.

bluebird bio, Inc.

bluebird bio, Inc., founded in 2010 and based in Cambridge, Massachusetts, developed gene therapies for sickle cell disease, β thalassemia, and cerebral adrenoleukodystrophy. The company continues to advance its portfolio through regulatory and commercial efforts, despite ongoing financial and operational challenges in the gene therapy sector. It remains focused on rare disease gene therapy delivery despite industry-wide challenges.

Biogen Inc.

Biogen Inc., established in 1978 and headquartered in Cambridge, Massachusetts, is focused on neurological and neurodegenerative disorders. Its gene therapy related efforts include advancing spinal muscular atrophy treatments and optimizing therapeutic regimens. Recent developments, including regulatory progress in SMA therapies, highlight ongoing efforts to enhance outcomes and support the broader gene augmentation landscape.

Other key players in the market are Sibiono GeneTech Co. Ltd., Gilead Sciences, Inc., Sangamo Therapeutics, Inc., Intellia Therapeutics, Inc., REGENXBIO Inc., Abeona Therapeutics Inc., Orchard Therapeutics plc, Sio Gene Therapies Ltd., Ultragenyx Pharmaceutical Inc., Krystal Biotech, Inc., Rocket Pharmaceuticals, Ltd., MeiraGTx Limited., Solid Biosciences Inc., GenSight Biologics S.A., Editas Medicine, Inc., CRISPR Therapeutics AG, Spark Therapeutics, Inc., Genprex, Inc., Poseida Therapeutics, Inc., Astellas Pharma Inc., Voyager Therapeutics, Inc., Coave Therapeutics, Precision BioSciences, Inc., and others.

Key Questions Answered in the Gene Therapy Market Report

• What was the gene therapy market value in 2025?
• What is the gene therapy market forecast outlook for 2026-2035?
• What major factors aid the demand for the gene therapy market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major gene therapy market trends?
• Which indication is expected to dominate the market segment?
• Which vector is expected to dominate the market segment?
• Who are the key players in the gene therapy market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?